HuLow Report issue

For profit Phase 2
Founded: Chicago IL United States (2014)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2015
NCT02614404
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

dihydroartemisinin (1 trial)

imatinib (gleevec) (1 trial)

piperaquine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 2)

Malaria, Falciparum (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3